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Background: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes caused by au-
toantibodies against desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3). Pemphigus vulgaris (PV) is the most common 
form of pemphigus. The aim of this study was to assess the correlation between the levels of anti-desmoglein 1 and 
3 autoantibodies and the severity of PV disease.
Material and Methods: Nineteen newly diagnosed patients with pemphigus vulgaris were enrolled in this study. The 
titers of Dsg in subjects by using enzyme-linked immunosorbent assay (ELISA) were done at diagnosis time-point, 
4th and 8th weeks after the initiation of treatment, and the correlation of antibodies with the oral and skin disease 
severity was evaluated. 
Results: The severity of cutaneous lesions was significantly correlated with anti-Dsg1 titer in all visits and the 
severity of mucosal lesions was correlated with the titer of Dsg3 in the third visit (<0.001, 0.001, 0.016 and 0.015 
P value, respectively).
Conclusions: Anti-Dsg-1 autoantibodies titers seem to be more useful in showing the extent of the disease and 
activity in pemphigus with mucocutaneous lesions.




Pemphigus is a group acquired autoimmune bullous skin 
disease characterized by the presence of IgG auto-anti-
bodies against keratinocyte cell surfaces of intercellu-
lar junctions. This leads to the loss of normal epithelial 
cell-to-cell adhesion (termed acantholysis) (1,2). Pem-
phigus affects 0.1-5.5% of the population per 100,000 
per year (3,4). The two main types of pemphigus are 
pemphigus vulgaris (PV) and pemphigus foliaceus. The 
other forms include erythematosus, vegetans, IgA pem-
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phigus, drug-induced pemphigus and paraneoplastic 
pemphigus (5,6). PV is the most common form of pem-
phigus, accounting for more than 80% of cases (4). PV 
is commonly linked to auto-antibodies against desmog-
lein 3 and in some cases, desmoglein 1. In PV patients, 
blisters are developed just superior to the basal cell layer 
in the epidermis causing chronic painful erosions in the 
oral cavity and flaccid blisters on normal-appearing skin 
(1,2,7). Clinical and histological examination, direct and 
indirect immunofluorescence and enzyme-linked immu-
nosorbent assays (ELISAs) are used in the diagnosis of 
pemphigus (8,9). Standard treatments for pemphigus 
are corticosteroids and immunosuppressive drugs. The 
patients’ responses to treatment vary per case and fre-
quent clinical relapses are reported (1,10,11). Therefo-
re, clinical follow-ups are advised and serum anti-Dsg 
antibody levels should be monitored. For follow-up and 
therapeutic management of pemphigus patients, autoan-
tibody titers, in particular, have been suggested. Hence, 
in this study, in order to evaluate the effectiveness of the 
ELISA assay as a follow-up tool for the management 
of pemphigus therapy, we sought to determine the titer 
of anti-desmoglein 1 and 3 auto-antibodies at the onset 
of the disease and during follow-up period (4th and 8th 
weeks after the initiation of treatment) and assess its as-
sociation with the severity of the disease.
Material and Methods
This study was conducted on newly diagnosed patients 
with PV who referred to Qaem Hospital, Imam Reza 
Hospital and Oral Medicine Department of Mashhad 
Dental School. The study protocol was approved by the 
institutional ethical committee. Diagnosis of PV was 
performed based on clinical examination, histopatholo-
gy, and direct immunofluorescence. 
Patients were selected based on the following criteria: 
Personal consent for entering the study, clinical confir-
mation of PV based on histopathology and direct im-
munofluorescence, in addition to having no previous 
treatment of lesions before entering the study. The cri-
teria for excluding patients from the study included lack 
of participation in all follow up sessions, other types of 
pemphigus (pemphigus foliaceus or erythematosus).
Based on the inclusion and exclusion criteria, 19 pa-
tients were enrolled in this study. Demographic infor-
mation including age, sex, and PV phenotype (mucosal, 
and mucocutaneous) were fully recorded. The severity 
score for both mucosal and cutaneous involvement was 
calculated as well. For all patients, the procedure was 
described and a written consent was obtained from each 
patient. 5 cc blood samples were collected from the pa-
tients. Samples were stored at -70 ° C until the laboratory 
investigation were done. Because the sampling time is 
effective in response due to circadian variation, samples 
were collected between 09:00-11:00. Serum samples 
were collected before the treatment and after the first 
and the second follow-ups. Given that the average reco-
very time is usually between the third and the fifth weeks 
after the beginning of treatment, the first follow-up an-
tibody titration from the patients was performed in the 
fourth week after the beginning of the treatment and the 
second titration in the eighth week.
To detect autoantibodies by ELISA, anti-desmoglein 1 
and 3 recombinant proteins were used (Euroimmun, Lü-
beck, Germany). Following the manufacturer’s instruc-
tions, a cut-off value of>20 U/mL considered positive. In 
order to determine the correlation between the levels of 
anti-desmoglein 1 and 3 autoantibodies and the severity 
of mucosal and cutaneous involvement, the severity of 
pemphigus disease at the onset and during the follow 
ups was calculated as follows (12,13):
Oral mucosa score:
0= No lesion.
1 = Minor activity (only buccal mucosal, lingual, labio-
gingival, palatal or pharyngeal involvement).
2 = Moderate activity (buccal and labiogingival, lingual, 
palatal or pharyngeal involvement).




1= Up to five blisters and/or erosions.
2= 5–20 blisters and/or erosions.
3= >20 or extensive and confluent blisters and/or ero-
sions.
Meanwhile, all patients were treated by a dermatologist 
with systemic corticosteroid (1-2 mg / kg) and an adju-
vant mainly azathioprine (2-3 mg/kg) or mycophenolate 
mofetil (2gr/day).
Descriptive and inferential statistics were used to analyze 
the data. Central dispersion indices, mean and standard 
deviation were used to describe the data. Data were 
analyzed using Chi-square, Spearman, Mann-Whitney 
and Friedman correlation coefficients. In all tests, a sig-
nificant level of 0.05 was considered with a confidence 
level of 0.95.
Results
This study was conducted on 19 patients diagnosed with 
PV, including 9 males and 10 females. The patients va-
ried in age between 17-73 years and the mean age of 
patients was 47.26 ± 15.11. 
Six patients (31.6%) had only mucosal lesions, and in 13 
patients (68.4%) both skin and oral mucosa were invol-
ved. Baseline characteristics of the subjects are provided 
in Table 1.
Among 19 patients with PV, ELISA identified positive 
values of anti-Dsg3 auto-antibodies in 18 (95%) patients 
at the time of the initial diagnosis and in 16 (84%) and 
11 (57%) after the first and the second follow ups, res-














Severity of mucosal 
involvement
Score 0 0 (0%)
Score 1    3 (15.7%)
Score 2 10 (52.6%)
Score 3    6 (31.5%)
Severity of cutaneous 
involvement
Score 0   6 (31.5%)
Score 1 3 (15.7%)
Score 2  3 (15.7%)









Table 1: Baseline characteristics of the study participants. pectively. Positive values of anti-Dsg1 auto-antibodies 
were detected in 12 (63%) patients with PV at the time 
of diagnosis and in 8 (42%) and 11 (57%) patients after 
the first and the second follow ups, respectively (Table 
2).
The average Dsg3 titer from the baseline (the diagnosis 
time-point) until the third session (second follow-up) 
was downregulated. The average titer of Dsg1 was 
downregulated from the first session (diagnosis) to the 
second session (second follow-up) and upregulated from 
the second to the third session (Table 3). 
Based on the Wilcoxon test, there was a significant de-
crease for the mean titer of anti-Dsg1 auto-antibodies 
between the first and the second sessions (P = 0.006) and 
between the first and the third sessions (P = 0.025), but 
the change between the second and third sessions (P = 
0.918) was not meaningful. The mean titer of anti-Dsg3 
auto-antibodies showed a significant decrease among all 
sessions, such that between the first and the second ses-
sions (P = 0.005), between the first and third sessions (P 
<0.001) and between the second and third sessions (P = 
0.001), there was a significant difference.
According to the Spearman test, in all sessions, the co-
rrelation between the Dsg1 titer and the severity of cuta-
neous lesions as well as between the titer of Dsg3 in the 
third session and the severity of mucosal lesions was sta-
tistically significant (P value <0.001, 0.001, 0.016 and 
0.015, respectively). However, the titer of Dsg3 with the 
severity of cutaneous lesions, the titer of Dsg1 with the 
severity of mucosal lesions, and the titer of Dsg3 with 
the severity of mucosal lesions in the first and the second 
sessions did not show a significant relationship (Table 
4, Fig. 1).
Discussion
Pemphigus is a potentially lethal mucocutaneous bliste-
ring disease whose early diagnosis and timely treatment 
is critical for the patients. The clinical course of pemphi-
gus varies significantly, and it is a challenge to predict 
No. (%) of positive patients 
  Anti-Dsg1 Anti-Dsg3
Diagnosis First follow up Second follow up Diagnosis First follow up Second follow up
Positive (>20 U/
mL) 12(63%) 8 (42%) 11 (57%) 18(95%) 16 (84%) 11 (57%)
Table 2: Presence of anti-Dsg3 and anti-Dsg1 antibodies in PV patients in the diagnosis and follow up sessions.
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Anti-Dsg1 (U/L) Anti-Dsg3 (U/L)
Diagnosis First follow up Second follow up Diagnosis First follow up Second follow up
Mean±S.D. 104.75±102.09 66.24±90.06 78.31±90.71 180.37±97.64 151.64±95.59 72.58±87.57
Table 3: Mean of anti-Dsg3 and anti-Dsg1 antibodies in PV patients in the diagnosis and follow up sessions.
Anti-Dsg1 Anti-Dsg3
Diagnosis First follow up
Second 







coefficient 0.737 0.820 0.545 0.248 0.046 0.231





coefficient -0.164 0.106 0.253 0.309 0.254 0.549
P value 0.502 0.667 0.297 0.198 0.294 0.015
Table 4: Relationship between anti-Dsg3 and anti-Dsg1 auto-antibodies and the severity of skin/ mucousal involvement during diagnosis and 
follow-up sessions based on the Spearman test.
Fig. 1: Association between severity of cutaneous lesions and Dsg1 titers in pemphigus vulgaris (P < 0.001, 
r = 0.51) in the first follow up session.
it only on the basis of clinical evaluation (1). Therefore, 
it can be helpful to apply a serial detection of anti-Dsg 
titers with the purpose of monitoring the disease activity 
in addition to managing the therapy. 
The aim of this investigation was to evaluate the correla-
tion between serum desmoglein 1 and 3 auto-antibodies 
and the severity of disease in patients with pemphigus 
vulgaris. In our study, 19 patients with PV were exa-
mined for anti-Dsg1 and anti-Dsg3 auto-antibodies ti-
tration by the ELISA method and their association with 
the severity of disease was assessed at the time-point of 
diagnosis, and after 4th and 8th weeks. 
Overall, we found a significant correlation between the 
anti-Dsg1 auto-antibody titer and the severity of cuta-
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neous lesions in all sessions as well as between the titer 
of anti-Dsg3 and the severity of mucosal lesions in the 
third session.
Numerous studies have explored the relationship be-
tween desmoglein level and the severity of pemphigus 
disease. A number of authors have found that the levels 
of antibodies against Dsg1 was positively correlated 
with an increase in the severity of cutaneous lesions and 
elevated levels of anti-Dsg3 antibodies was found to 
correlate with the severity of mucosal involvement (12-
16). In contrast, Belloni-Fortina A et al. reported a rela-
tionship between the titer of anti-Dsg3 and the severity 
of both cutaneous and mucosal lesions, while they have 
found that anti-Dsg1 titer relates only to the severity of 
mucosal lesions (17).
Moreover, Mortazavi et al. and De D et al. showed that 
the degree of skin damages significantly enhanced upon 
an increase in the anti-Dsg1 concentrations, but they 
found no significant correlation between anti-Dsg3 an-
tibodies and the severity of oral mucosal lesions (18,19). 
Abasq et al. have reported that in PV patients, the anti- 
Dsg3 titer is not necessarily linked to the clinical course 
of mucosal lesions (20). Furthermore, Daneshpazhuh 
et al. previously reported that Dsg3 index values had a 
correlation with the severity of both cutaneous and mu-
cosal diseases, while the anti-Dsg1 antibody levels only 
correlated with the severity of cutaneous lesions (21).
These discrepancies could be attributed to the low sam-
ple size in each of the reported studies in addition to ge-
netic variations, and the varying criteria that are used to 
assess the disease severity (1,22).
In conclusion, anti-Dsg1 auto-antibody titers seem to be 
more useful for monitoring the extent of the disease and 
activity in pemphigus with mucocutaneous lesions. The 
anti-Dsg3 auto-antibody titers can be used for diagnostic 
purposes, but it fails to indicate disease activity. Multi-cen-
tre studies with a larger number of patients and a long-term 
follow-up may provide additional information for the inter-
pretation of findings in association with the disease course. 
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